Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020


The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies.

Publication date
September 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report.


The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


This report provides details of the latest discovery agreements announced in the healthcare sector.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all discovery stage partnering deals announced since 2014 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.


Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.


Chapter 5 provides a review of discovery stage deal making since 2014. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.


Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.


Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 


Chapter 8 provides a comprehensive listing of the top 25 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 


Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2014, where a contract document is available in the public domain.


Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2014.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2014.


In addition, a comprehensive appendix of all discovery deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.


Key benefits


Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 provide the reader with the following key benefits:


  • In-depth understanding of discovery stage deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Insight into the terms included in a discovery stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.


Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 include:


  • Trends in discovery stage dealmaking in the biopharma industry since 2014
  • Analysis of discovery stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life discovery stage deals
  • Access to over 3,000 discovery stage deals
  • The leading discovery stage deals by value since 2014
  • Most active discovery stage dealmakers since 2014
  • The leading discovery stage partnering 2014


In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020, the available contracts are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides comprehensive access to available deals and contract documents for over 3,000 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides the reader with the following key benefits:


  •  In-depth understanding of discovery stage deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 3,000 discovery stage deals together with contract documents if available
  • Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Identify leading discovery stage deals by value since 2014
  • Identify the most active discovery stage dealmakers since 2014
  • Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Why do companies partner at discovery stage?


2.1. Introduction

2.2. The role of discovery stage partnering

2.2.1. In-licensing at discovery stage

2.2.2. Out-licensing at discovery stage

2.3. Difference between discovery, preclinical and clinical stage deals

2.4. Reasons for entering into discovery stage partnering deals

2.4.1. Licensors reasons for entering discovery stage deals

2.4.2. Licensees reasons for entering discovery stage deals

2.5. The future of discovery stage partnering deals


Chapter 3 – Discovery stage deal strategies and structure


3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical/biotech Discovery and preclinical stage partnering case studies Case study: LEO Pharma - 4SC Case study: Heptares Therapeutics - Cubist Case study: Incyte – Agenus Bio Case study: Janssen Pharmaceutical - Evotec

3.2.2. Partnering later in pharmaceutical/biotech Clinical stage partnering case studies Case study: Servier – GeNeuro Case study: Teva – Xenon Pharmaceuticals Case study: AstraZeneca - Ardelyx Case study: Baxter – Onconova Therapeutics

3.3. Early and later stage partnering – a risk/cost comparison

3.4. What do companies spend on discovery, preclinical and clinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure licensing agreements

3.6.1.a. Case study : Pfizer – Spark Therapeutics

3.6.1.b. Case study : Contrafect – Trellis Bioscience

3.7. Multicomponent discovery stage partnering agreements

3.7.1.a. Example multicomponent early stage clauses

3.7.1.a. Case study: Tracon – Boehringer Ingelheim – Macrogenics

3.7.1.b. Case study: Fibrocell Science – Intrexon


Chapter 4 – Discovery stage partnering payment strategies


4.1. Introduction

4.2. Discovery stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments Issues affecting royalty rates Royalties on combination products Case study: Scripps Research Institute-Cyanotech Guaranteed minimum/maximum annual payments Royalty stacking Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments


Chapter 5 – Trends in discovery stage deal making


5.1. Introduction

5.2. Discovery stage partnering over the years

5.2.1. Attributes of discovery deals

5.3. Discovery stage partnering by deal type

5.4. Discovery stage partnering by disease type

5.5. Partnering by discovery stage technology type

5.6. Discovery stage partnering by most active company since 2014


Chapter 6 – Payment terms for discovery stage partnering


6.1. Introduction

6.2. Guidelines for discovery stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Discovery stage payment terms – deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Discovery stage headline values

6.4.2. Discovery stage deal upfront payments

6.4.3. Discovery stage deal milestone payments

6.4.4. Discovery stage royalty rates


Chapter 7 – Leading discovery stage deals


7.1. Introduction

7.2. Top discovery stage deals by value


Chapter 8 – Top 25 most active discovery stage dealmakers


8.1. Introduction

8.2. Top 25 most active discovery stage dealmakers


Chapter 9 – Discovery stage partnering contracts directory


9.1. Introduction

9.2. Discovery stage deals with contracts 2014 to 2020


Chapter 10 – Discovery stage deal making by development stage


10.1. Introduction

10.2. Deals by discovery stage




Appendix 1 – Discovery stage dealmaking by companies A-Z

Appendix 2 – Discovery stage dealmaking by industry sector

Appendix 3 – Discovery stage dealmaking by stage of development

Appendix 4 – Discovery stage dealmaking by therapy area

Appendix 5 – Discovery stage dealmaking by technology type


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from CurrentPartnering


Table of figures


Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Components of the pure licensing deal structure
Figure 3: Payment options for discovery stage partnering deals
Figure 4: Issues affecting royalty rates
Figure 5: Discovery stage partnering frequency 2014- 2020
Figure 6: Discovery stage partnering by deal type since 2014
Figure 7: Discovery stage partnering by disease type since 2014
Figure 8: Discovery stage partnering by technology type since 2014
Figure 9: Top 25 most active discovery stage dealmakers, 2014 to 2020
Figure 10: Review of median upfront payments for discovery stage deals
Figure 11: Review of median milestone payments for discovery stage deals
Figure 12: Review of median royalty payments for discovery stage deals
Figure 13: Discovery stage deals with a headline value
Figure 14: Discovery stage deals with an upfront value
Figure 15: Discovery stage deals with a milestone value
Figure 16: Discovery stage deals with a royalty rate value
Figure 17: Top discovery stage deals that exceeds $1 billion in deal value since 2014
Figure 18: Most active discovery stage dealmakers 2014 to 2020

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1CellBiO, 1ST Biotherapeutics, 2A, 3B Pharmaceuticals, 3SBio, 4D Molecular Therapeutics, 4D Pharma, 10X Genomics, 14M Genomics, 22nd Century, 23andMe, 48Hour Discovery, A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, A*STAR’ Institute of Molecular and Cell Biology, A-Alpha Bio, A.I. Squared, A1M Pharma, A2A Pharmaceuticals, Abbvie, Abby Grace Foundation, Abcam, AbCellera, AbCheck, Abcuro, Abeona Therapeutics, Abide Therapeutics, Abilita Bio, Ab Initio, ABL Bio, Ablexis, Ablynx, AbMed, Abpro, Abramson Cancer Center, Abveris, Abzena, Academic Drug Discovery Consortium, Acceleron Pharma, Accelovance, Accenture, ACEA Biosciences, Acerta Pharma, Acetylon Pharmaceuticals, AC Immune, Actavis (name changed to Allergan), Actelion, Actinium Pharmaceuticals, ActoGeniX, AcuraStem, Adagene, AdAlta, Adapsyn Bioscience, Adaptate Biotherapeutics, Adaptimmune, Adaptive Biotechnologies, Adaptive Phage Therapeutics, ADC Therapeutics, Adimab, AdoRx Therapeutics, ADT Pharmaceuticals, Aduro BioTech, Advaita, Advaite, Advanced Biological Laboratories, Advanced Proteome Therapeutics, Advaxis, Adverum Biotechnologies, Adynxx, Aelan Cell Technologies, Aeras, AEterna Zentaris, Aetion, Aevi Genomic Medicine, Aevitas Therapeutics, Affibody, Affimed Therapeutics, Affinivax, AFFiRiS, Affymetrix, AffyXell Therapeutics, Afraxis, AgBiome, Age Labs, Agendia, Agensys, Agenus Bio, AgeX Therapeutics, Agilent Technologies, Agilis Biotherapeutics, AgomAb Therapeutics, AgonOx, AGTC, AiCuris, AiVita Biomedical, AKESOgen, Akili Interactive Labs, Akouos, Akoya Biosciences, Akrevia Therapeutics, Akriveia Therapeutics, Albert Einstein College of Medicine, Albumedix, Alderley Analytical, Aldevron, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, Algenex, AliHealth, AlivaMab Discovery Services, Alize Pharma, ALK-Abello, Alkahest, Alkermes, Allakos, Allele Biotechnology and Pharmaceuticals, Allen Institute for Brain Science, Allergan, Allied-Bristol Life Sciences, Alligator Bioscience, Allogene Therapeutics, Almac Discovery, Almac Group, Almirall, Alnylam Pharmaceuticals, Alpine Immune Sciences, ALS Association, ALS Biopharma, Altasciences, Alteogen, Alytas Therapeutics, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimer's Foundation of America, Alzheimer's Research UK, Alzheimer Society Research, Alzheimers Research UK, Amarantus BioSciences, Amarna Therapeutics, Amazon Web Services, Ambrx, Ambys Medicines, American Academy of Ophthalmology, American Association for Cancer Research, American BriVision, American Cancer Society, American Diabetes Association, American Lung Association, American National Multiple Sclerosis Society, American Skin Association, American Society of Clinical Oncology (ASCO), American Society of Hematology, Amfora, Amgen, Amicus Therapeutics, AmorChem, AmpliPhi Biosciences, AMR, AMRA, Amunix, Amyris, AnaBios, Anaeropharma, Analysis Group, Analytical Biological Services, Analytics Engines, AnaMar, ANANDA Scientific, Anandia Laboratories, Anchiano Therapeutics, AnGes MG, Angle, Anika Therapeutics, Anima Biotech, Anji Pharma, Annette Funicello Research Fund for Neurological Diseases (AFRFND), Annoroad, ANP Technologies, Antengene, Anterios, Anthem, Antibody Solutions, Antikor Biopharma, Antitope, Apeiron Biologics, Aphios, Applied BioMath, APRINOIA Therapeutics, Aptahem, Aptamer Therapeutics, Aptose Biosciences, Aptuit, Aqilion, Aquinnah Pharmaceuticals, Arbele, Arbor Biotechnologies, Arbutus, Arcadia Biosciences, Arcturus Therapeutics, Ardelyx, Ardent Mills, Arena Pharmaceuticals, Ares Genetics, Ares Life Sciences, arGEN-X, argenx, Argos Therapeutics, Ariad Pharmaceuticals, Ariana Pharma, Aridis Pharmaceuticals, Arisaph Pharmaceuticals, Arix Bioscience, Ark Biosciences, ARMO Biosciences, Aro Biotherapeutics, Arpeggio Biosciences, Arrakis Therapeutics, Array Biopharma, Arrevus, Arrow Pharmaceuticals, Artelo Biosciences, Artes Biotechnology, Artialis, Artios Pharma, Artizan Biosciences, Arvinas, Arzeda, Asahi Kasei, Asana Biosciences, Asceneuron, Ascenion, ASKA Pharmaceuticals, Asklepios Biopharmaceutical, Aspira Scientific, Aspyrian Therapeutics, Astellas Pharma, Astex Pharmaceuticals, Asthma UK, AstraZeneca, Atara Biotherapeutics, Ataxion, aTen Therapeutics, Athenex, Atomwise, Atossa Genetics, Atrapos Therapeutics, Atreca, Atropos Therapeutics, ATUM, Atvio Biotech, aTyr Pharma, Auburn University, Audentes Therapeutics, Audion Therapeutics, AUM Biotech, Aural Analytics, Aurigene Discovery Technologies, Auris Medical, Auron Therapeutics, Australian Department of Health and Ageing, Australian Foundation for Diabetes Research, Australian Research Council, Autifony Therapeutics, Autodesk, Autolus, Avacta, Avactis Biosciences, Avalon GloboCare, AvantGen, Avidity Biosciences, Avidity NanoMedicines, Avita Medical, Axcelead Drug Discovery Partners, Axcella, Axiogenesis, AxioMx, Axis Therapeutics, Axovant Sciences, Axxam, AyoxxA Biosystems, AzurRx BioPharma, B-MoGen Biotechnologies, Babraham Institute, Bacit, Bactevo, Barbara Ann Karmanos Cancer Institute, Baruch S Blumberg Institute, BASF, Basilea Pharmaceutica, Batavia Biosciences, Battelle, Baudry Laboratory, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Healthcare, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, Baylor Miraca Genetics Laboratories, BCD Bioscience, BD Biosciences, Beacon Discovery, Beactica, Beam Therapeutics, BeiGene, Bellerophon Therapeutics, Bellicum Pharmaceuticals, Ben-Gurion University, Benchwise, BenevolentAI, Benitec Biopharma, Berg, Berkeley Lights, Beroni Group, Bertin Pharma, Beta Therapeutics, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, Beyond Batten Disease Foundation, BGN Technologies, Biametrics, Bicycle Therapeutics, Bill and Melinda Gates Foundation, BIND Therapeutics, Bio-Cancer Treatment International, Bio-Rad Laboratories, Bio-Techne, BioArctic Neuroscience, biOasis Technologies, BIOASTER, BioAtla, BioBlast Pharma, Bioblock, BioBright, Biocept, BioCision, Biocodex Microbiota Foundation, BioCurate, Biodextris, BioFluidica, Biofourmis, Biogen, Biognosys, Biohaven Pharmaceutical Holding, BioInvent, BioIVT, BioLegend, BiolineRX, Biolin Scientific, BioLite Japan, Biomed Elements, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), BioMed Realty Trust, BioMed X Innovation Center, bioMerieux, Biomica, Biomillenia, BioMotiv, Biomunex Pharmaceuticals, BiomX, BioNano Genomics, Bioneer, Bionetix, Bioniz Therapeutics, BioNovion, BioNTech, BionX Medical Technologies, Bioo Scientific, Bio Palette, BioPontis Alliance, BioReference Laboratories, Biorelate, BioReliance, BioRestorative Therapies, Biosceptre International, Biosearch Technologies, BioSolveIT, Biostar Pharmaceuticals, Biotechnology and Biological Sciences Research Council (BBSRC), Biotem, Biothera, Biotheus, BioVaxys, Bioverativ, BioVersys, BioXcel, Bioz, BirchBioMed, Bird Foundation, Bit Bio, Blackfynn, BlackThorn Therapeutics, BlinkBio, BliNK Biomedical, Bliss Biopharmaceutical, Blockchain Global, Bloom Burton, Bloom Science, Bluebird Bio, Blue Buffalo Company, Blue Cross Blue Shield Association, Bluefield Innovations, Blueprint Medicines, BlueRock Therapeutics, Blue Water Vaccines, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bonbouton, Bone Therapeutics, Bonnie J. Addario Lung Cancer Foundation, Boragen, Boston Biomedical, BostonGene, Boston University, Boston University School of Medicine, Botanisol, Boulos and Cooper Pharmaceuticals, Bpifrance, Brain & Behavior Research Foundation, Brain Biomarker Solutions in Gothenburg, Brain Science Foundation, BravoVax, BRCA Foundation, Breath Diagnostics, BrickBio, Brickell Biotech, BridgeBio Pharma, Brigham and Women's Hospital, BrightFocus Foundation, Brighton Biotech, Brii Biosciences, BRIM Biotechnology, Bristol-Myers Squibb, British Pharmacological Society, Broad Institute, Brown University, Buck Institute for Age Research, BullFrog AI, Burnet Institute, C2N Diagnostics, C4 Therapeutics, C4X Discovery, Caerus Discovery, Caladrius Biosciences, Calico, California Institute for Biomedical Research, California Institute for Quantitative Biosciences (QB3), California Institute for Regenerative Medicine, California Institute of Technology, Calimmune, Calithera Biosciences, Calixar, Calyxt, Cambridge Enterprise, Camino Pharma, CAMP4 Therapeutics, CANbridge Life Sciences, Cancer Australia, Cancer Immunotherapy Trials Network, Cancer Prevention and Research Institute of Texas, Cancer Research Institute, Cancer Research Technology, Cancer Research UK, Cantab Anti-infectives, Capnia, Capricor Therapeutics, CARB-X, Carbiotix, Cardiff University, Cardinal Partners, Cardurion Pharmaceuticals, Caribou Biosciences, Caris Life Sciences, Carmentix, Carmot Therapeutics, Carna BioSciences, Carnot BioSciences, Carolina BioOncology Institute, CARsgen, Cartana, Cartherics, Casebia Therapeutics, Case Western Reserve University, Casma Therapeutics, CasZyme, Catalan Institute of Nanotechnology (ICN), Catalent, Catholic University Leuven, CavoGene LifeSciences, CBT Pharmaceuticals, Cedars-Sinai Medical Center, CEITEC, Celgene, Cell2in, Celladon, Cellaria Biosciences, Cellecta, Cellectar Biosciences, Cellect Biotechnology, Cellectis, Cellesce, CELLINK, Cell Medica, Cell Mogrify, Cellthera Pharma, Cell Therapy Catapult, Celltrion, Cellular Biomedicine, Cellular Dynamics International, Cellular Research, Celmatix, Celonic, Celsius Therapeutics, Cenix BioScience, Centene, Center for Biomarker Research in Medicine, Center for Human Genetics and Laboratory Medicine, Center for Human Immunology, Autoimmunity and Inflammation, Center for Infectious Disease Research, Center for iPS Cells Research and Application, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Centre For Proteomic & Genomic Research, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Centre Hospital University - Bordeaux, Centre Leon Berard, Centre National de Biologie Expérimentale, Centre National de la Recherche Scientifique, Century Therapeutics, Cepheid, Cerevance, Certara, Cerveau Technologies, Ceva Sante Animale, Cevec Pharmaceuticals, Chan Zuckerberg Initiative, Chaperone Technologies, Charles River Laboratories, CHDI Foundation, Checkpoint Therapeutics, ChemDiv, ChemRar High-Tech Center, Chiesi Farmaceutici, Children's Heart Foundation, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Philadelphia, Children's Hospital Of Wisconsin, Children's Medical Research Institute, Children's National Health System, China-Singapore Guangzhou Knowledge City, China National Biotech Group (CNBG), China Southeast University, Chinese Academy of Agricultural Science, Chinese Academy of Sciences, Chiome Bioscience, Chiromics, Chongqing Lummy Pharma, Christian Doppler Research Association, Chronos Therapeutics, Chugai Pharmaceutical, Cidara Therapeutics, Cincinnati Children’s Hospital Medical Center, Cinda Bio-Pharmaceutical, Circuit Clinical, Circuit Therapeutics, Cisen Pharma, City of Hope, Civetta Therapeutics, Clalit Health Services, Clarity Pharmaceuticals, Cleara Biotech, Clearbridge Biomedics, ClearLight Diagnostics, ClearPath, Clene Nanomedicine, Cleveland Clinic, Cleveland HeartLab, Cleveland University Hospitals, Clevexel Pharma, Cloud Pharmaceuticals, Clover Therapeutics, Clovis Oncology, CNA Development, Co-Diagnostics, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Cocrystal Pharma, Codexis, Codiak BioSciences, COFCO Group, Cognition Therapeutics, Cohen Veterans Bioscience, Cold Spring Harbor, Collaborative Trajectory Analysis Project, Columbia University, Columbia University Medical Center, Complix, Compugen, Concept Life Sciences, Concerto HealthAI, Confo Therapeutics, Congenica, Conkwest, Connecticut Children’s Medical Center, ConsortiaTX, Consortium AI, Context Therapeutics, Contextual Genomics, ContraFect, ContraVir Pharmaceuticals, Convelo Therapeutics, Cooperative Research Centre for Cell Therapy Manufacturing, Cord Blood Registry, CoreBiome, Corestem, Cornell University, Coronado Biosciences, Corporation for Biological Research, Corteva Agriscience, Cortexyme, Corvidia Therapeutics, COTA, COUR Pharmaceutical, Courtagen Life Sciences, Covalab, Covalent Data, Covaris, Create Vaccine Company, Creative Destruction Lab, Creative Medical Technologies, Crescendo Biologics, Cresset, Crestone Pharma, CRISPR Therapeutics, Cristal Therapeutics, Crohn's and Colitis Foundation of America, Crossbeta Biosciences, Crown Bioscience, Crystal Bioscience, CSL Behring, CTI BioPharma, Cue Biopharma, Cullinan Oncology, Cumberland Emerging Technologies, Cumberland Pharmaceuticals, Curable, Curadev Pharma, CureCell, Cure Duchenne, Cure Sanfilippo Foundation, Cure SMA, Cures Within Reach, Curetis, CureVac, Curie-Cancer, Curiox Biosystems, Curis, Cyclenium Pharma, Cyclica, Cyclotek, Cynata Therapeutics, Cypher Genomics, Cyrus Biotechnology, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Cystinosis Research Foundation, CytoLumina Technologies, CytomX Therapeutics, Cytoo, CytoReason, CytoSen Therapeutics, Cytovant Sciences, CYTOVIA Therapeutics, Cytox, Daewoong Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dalhousie University, Dana-Farber Cancer Institute, DarwinHealth, Datavant, David H. Koch Institute for Integrative Cancer Research, Da Volterra, DayTwo, Debiopharm, Decibel Therapeutics, deCODE Genetics, Deerfield Management, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, DefiniGEN, DeGregorio Family Foundation, Deinove, Dementia Consortium, Dementia Discovery Fund, Denali Therapeutics, Dendreon, DendroCyte, Department of Defense, Department of Economic development of Montgomery County, Department of Health and Human Services, Department of Veterans Affairs, DePuy, Dermala, Dermelix Biotherapeutics, Desktop Genetics, DestiNA Genomics, Devonian Health Group, Dewpoint Therapeutics, DiamiR, Diamond Light Source, Diatheva, DiCE Molecules, Dicerna Pharmaceuticals, Dimension Therapeutics, DiNAQOR, Disc Medicine, Distributed Bio, DNAnexus, DNA Script, DNAtrix, Dolomite Bio, Domainex, Domain Therapeutics, Dorian Therapeutics, Dow AgroSciences, Dr. Susan Love Research Foundation, Dragonfly Therapeutics, Dresner Foundation, Drugs for Neglected Diseases Initiative, Drukier Institute for Children's Health, Dualogics, Duke Clinical Research Institute (DCRI), Duke University, Dyadic International, DyNAbind, Dynamic Combinatorial Chemistry, DZNE German Center for Neurodegenerative Diseases, E-Scape Bio, E-Therapeutics, E.T. Horn, E3x Bio, Eagledream Health, Eagle Genomics, ECM Therapeutics, Ecole Polytechnique Federale de Lausanne, Edge Therapeutics, Edico Genome, EdiGene, Edison Nation Medical, Edison Pharmaceuticals, Editas Medicine, eFFECTOR Therapeutics, Eirion Therapeutics, Eisai, Eisai Inc, Elanco, Elasmogen, Elevian, Eli Lilly, Elixirgen, Ellison Medical Foundation, Elpis Biomed, Elpiscience, Elsevier, Elucidata, Embark Biotech, EMD Serono, Emendo Biotherapeutics, Emergence Therapeutics, Emergent BioSolutions, Emergex Vaccines, Emory University, Empirico, Enamine, EnBiotix, Encycle Therpaeutics, Endo Pharmaceuticals, Energesis Pharmaceuticals, enGene, Engineered Medical Solutions, Engitix, Enigma Biomedical, Enleofen Bio, Enlibrium, Enterome Bioscience, Enthera, Enumeral Biomedical, ENYO Pharma, EpiBiome, Epic Sciences, Epilepsy Society, Epivax, Epizyme, Erasmus University Medical Center, ERS Genomics, Ervaxx, ES Cell International, Escient Pharmaceuticals, Esophageal Cancer Awareness Association, Essex Bio-Technology, Eternygen, eTheRNA immunotherapies, Euprotec, Eureka Eurostars, Eureka Therapeutic, Eurofins Discovery, Eurofins Genomics, European Bioinformatics Institute, European Commission, European Equity Partners, European Laboratory Research & Innovation Group, European Organization for Research and Treatment of Cancer, European Union, European Union Regional Development Fund, Evaxion Biotech, Evelo Biosciences, Evolva, Evonetix, Evotec, Evvivax, Exagen Diagnostics, Excision BioTherapeutics, Exelixis, Exicure, Exiqon, Exonics Therapeutics, Exosome Sciences, Exovita Biosciences, Expansion Therapeutics, Expesicor, ExpreS2ion Biotechnologies, ExScientia, F-Star, F1 Oncology, F2G, Fabric Genomics, Facio Therapies, Faron Pharmaceuticals, Fate Therapeutics, Fatro, Fauna Bio, Federal Ministry of Education and Research (BMBF), Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Feldan Therapeutics, Felicitex Therapeutics, Femtogenix, Ferring Pharmaceuticals, FetoLumina Technologies, Fibriant, Fidelta, Finnish Funding Agency for Technology and Innovation (TEKES), Firebrand Therapeutics, FirstString Research, FIT Biotech, Five Prime Therapeutics, Flatiron Health, Flemish agency for Innovation by Science and Technology, Florida Atlantic University Research, Florida International University, Florida State University, Flow Pharma, Fluidigm, Folia Biotech, Fondazione Telethon, Food and Drug Administration (FDA), Forendo Pharma, Forge Therapeutics, FORMA Therapeutics, Fortress Biotech, Forty Seven, Fosun Kite Biotechnology, Foundation Fighting Blindness, Foundation for Innovative New Diagnostics, Foundation for the Children of the Californias, Foundation Medicine, Four Points Innovation, Fox Chase Cancer Center, Francis Crick Institute, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Freenome, French Alternative Energies and Atomic Energy Commission, French National Institute for Agricultural Research, Frequency Therapeutics, Friedreichs Ataxia Research Alliance, Front Range Biosciences, FSD Pharma, Fudan University, Fujifilm, Fujitsu Laboratories, Fujitsu Laboratories of America, Fulcrum Therapeutics, Fundacion Medina, Fundacion Progreso y Salud, Fusion Antibodies, Fusion Pharmaceuticals, Fuzionaire Diagnostics, Gadeta, Gain Therapeutics, Galapagos, Galaxy Biotech, Galderma, Galmed Pharmaceuticals, GamaMabs Pharma, Garvan Institute of Medical Research, GATC Biotech, Gatehouse Bio, Gateway for Cancer Research, GB Sciences, GC LabCell, GC Pharma, GE Healthcare, Geisel School of Medicine at Dartmouth, Geisinger Health System, GEn1E Lifesciences, Gen9, Genagon Therapeutics, GenAhead Bio, Gencia Biotech, Genea Biocells, GeneBay, GeneCentric Therapeutics, Genective, GeneData, GenEdit, GeneDX, Genentech, Geneos Therapeutics, GenesisCare, Genestack, Genethon, Genetic Analysis, Genetic Technologies, Genetron Health, Genevant Sciences, Genewiz, Genfit, Genialis, Genisphere, Genmab, Genocea Biosciences, Genome BC, Genome Canada, GenomeDx, Genomenon, Genomeon, Genomics, Genomics England, Genomic Vision, Genoox, Genor Biopharma, Genosco, genOway, Genpact, GenScript USA, Genticel, Gentris, GenVec, Genzyme, George Mason University, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, George Washington University, Georgia State University, GeoVax, German Cancer Research Center, German Ministry for Education and Research, Gestion Univalor, Gilead Sciences, Ginkgo BioWorks, Glactone Pharma, Gladstone Institutes, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Alzheimer's Platform (GAP), Global Antibiotic Research and Development Partnership, Global Blood Therapeutics, Global Genomics Group, Glycocept, Glycostem Therapeutics, Glycotope Biotechnology, Glythera, GNA Biosolutions, Gnosis Bioresearch, GNS Healthcare, Golden Meditech, Goldfinch Bio, Goliver Therapeutics, Good Start Genetics, Good Therapeutics, Goodwin Biotechnology, Google, Gossamer Bio, GO Therapeutics, Grace Wilsey Foundation, Grail, Grameen Health, Gray Foundation, Great Ormond Street Hospital (GOSH), Green Cross LabCell, Griffith University, Grifols, Gritstone Oncology, Grunenthal, GT Apeiron Therapeutics, Guangzhou Xiangxue Pharmaceutical, Gubra, H3 Biomedicine, Hackensack Meridian Health, Hackensack University Medical Center, Halozyme Therapeutics, Hamad Bin Khalifa University, Hanmi Pharmaceutical, Hannover Medical School, Haplogen, Harbin Gloria Pharmaceuticals, Harbour Antibodies, Harbour Biomed, Harpoon Therapeutics, Harvard Medical School, Harvard Stem Cell Institute, Harvard University, HD Biosciences, Healthbox, Health Connexions, HealthCore, Healx, Hebrew University of Jerusalem, Heidelberg Pharma, Helen F Graham Cancer Center, Helix, Helix BioPharma, Helmholtz Centre for Infection Research, Helmholtz Zentrum Munchen, Helomics, Helperby Therapeutics, HemaCare, HemCon Medical Technologies, Hemogenyx, HemoShear, Henlius Biotech, Henry Ford Health System, Heraeus, Herlev Hospital, Hesperos, HiFiBio, Highline Therapeutics, HighRes Biosolutions, Histogenics, HitGen, HIV Interactions in Viral Evolution (HIVE) Center, Hoag Memorial Hospital Presbyterian, Hoffmann La Roche, Holobiome, Homology Medicines, Hongene Biotechnology, Hong Kong Baptist University, Hong Kong Polytechnic University, Hookipa Pharma, Horizon 2020, Horizon Discovery, Horizon Pharma plc, Hospital for Special Surgery, Hough Ear Institute, Hovione, Howard Hughes Medical Institute (HHMI), Hsiri Therapeutics, HTG Molecular Diagnostics, Hubrecht Organoid Technology, HudsonAlpha Institute for Biotechnology, Humabs BioMed, Human Cell Atlas, Human Longevity, Human Vaccines Project, Hummingbird Bioscience, hVIVO, Hydra Biosciences, Hyundai Hope On Wheels, I-mab, Ibex Medical Analytics, IBM, IBM Watson Health, Icagen, Icahn School of Medicine at Mount Sinai, iCarbonX, Ichor Medical Systems, Iconic Therapeutics, IDBS, iDD Biotech, IDEAYA Biosciences, Idera Pharmaceuticals, Idorsia, ID Pharma, IFM Therapeutics, iGEM, IGNITE Immunotherapy, Ikanik Farms, Iksuda Therapeutics, Iktos, Illumina, ImaBiotech, Imagia, ImaginAb, Imbrium Therapeutics, ImCheck Therapeutics, ImClone Systems, Imcyse, Imec, iMetabolic Biopharma, IMIDomics, Immatics Biotechnologies, Immatics US, ImmBio, Immugenyx, Immunaccel, Immune Biosolutions, Immune Design, Immuneering, ImmuNext, Immunic, ImmunoBiochem, ImmunoCellular Therapeutics, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunome, ImmunoPrecise Antibodies, ImmunoQure, Immunovaccine, Immunscape, ImmunXperts, Immuron, Immusol, Imperial College London, Imperial Innovations, Imugene, Imutex, IMV, Inception 5, Inception Sciences, Incyte, Indiana Biosciences Research Institute, Indiana University, InDi Molecular, Indivumed, Industrial Technology Research Institute, Infinity Pharmaceuticals, InflamaCORE, Inflammasome Therapeutics, Inflection Biosciences, InfoChem, Inhibrx, InMed Pharmaceuticals, INmune Bio, Innate Biologics, Innate Pharma, Innoplexus, Innosuisse, Innovate UK, Innovative Genomics Initiative (IGI), Innovative Medicines Initiative (IMI), Innovative Targeting Solutions, Innovent Biologics, INO Therapeutics, Inova Translational Medicine Institute, Inovio Pharmaceuticals, InProTher, Inserm, Inserm Transfert,, Insilico, Insilico Medicine, Insitro, InSphero, Instem, Institut Català d'Oncologia, Institut Curie, Institute for Basic Science, Institute for Bioscience and Biotechnology Research, Institute for Research in Biomedicine, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for Systems Biology, Institute of Bioengineering of Catalonia, Institute of Bioinformatics, Institute of Biophysics, Institute of Cancer Research, Institute of Crop Sciences, Institute Of Molecular Biotechnology, Institut Gustave Roussy, Institut Pasteur, Intarcia Therapeutics, IntegraGen, Integral Molecular, Integrated BioTherapeutics, Intellegens, Intellia Therapeutics, Intelligence Advanced Research Projects Activity (IARPA), Intellikine, INTELLiSTEM, Intermountain Healthcare, InteRNA Technologies, International AIDS Vaccine Initiative, International Association for the Study of Lung Cancer, International Myeloma Foundation, International Society for Neurovascular Disease (ISNVD), International Vaccine Institute (IVI), Interprotein, InterSystems, Intrexon, Invenra, Inventiva, Invetech, Invion, InVivoScribe, InVivo Therapeutics, Ionis Pharmaceuticals, IONTAS, Iovance Biotherapeutics, iProgen Biotech, Iproteos, iPS Academia Japan, Ipsen, IRBM, Isarna Therapeutics, Isogenica, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, iTeos Therapeutics, ITM Isotopen Technologien, Iveric Bio, Jackson Laboratory, Janssen-Cilag, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janus Pharmaceuticals, Japan Agency for Medical Research and Development, Jazz Pharmaceuticals, Jeffrey Modell Foundation, Jenner Institute, Jewish General Hospital, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu NHWA Pharmaceutical, Jing Medicine, Jitsubo, Jnana Therapeutics, Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Johnson & Johnson Vision, John Wayne Cancer Institute, Joslin Diabetes Center, Jounce Therapeutics, JPT Peptide Technologies, JS InnoPharm, JSR, Jubilant Biosys, Juno Therapeutics, Juntendo University, Just Biotherapeutics, Juvenescence, Juvenile Diabetes Research Foundation, Kadimastem, Kadmon Pharmaceuticals, Kaiima Bio-Agritech, Kaiser Permanente, Kaken Pharmaceutical, Kaleido Biosciences, Kallyope, Kamada, Karolinska Institute, Karyopharm Therapeutics, Kasios, Kazusa DNA Research Institute, KBP BioSciences, Keck Graduate Institute of Applied Life Sciences, Keck School of Medicine of USC, Keio Gijuku University, KemPharm, Keygene, KineMed, Kineta, Kinex Pharmaceuticals, KingMed Diagnostics, Kings College London, Kiniksa Pharmaceuticals, KinoPharma, Kite Pharma, Kiyatec, Kleo Pharmaceuticals, Knauer Scientific Instruments, Knopp Biosciences, KNOW Bio, Knudra Transgenics, Kobe University, Kodiak Sciences, Kogenix, KSQ Therapeutics, Kurma Life Sciences Partners, KWS SAAT, Kymab, Kymera Therapeutics, Kyn Therapeutics, Kyorin Pharmaceutical, Kyoto University, Kyowa Hakko Kirin, Kythera Biopharmaceuticals, Kyverna Therapeutics, Lab7 Systems, Lab1636, Labcyte, LabNetwork, Laboratory Corporation of America, Laboratory of Malaria Immunology and Vaccinology (LMIV), LA Cell, Lacerta Therapeutics, La Jolla Institute for Allergy & Immunology, La Jolla Pharmaceutical, LakePharma, Lakewood-Amedex, Lancet, Lantern Pharma, Lantheus Holding, Laurel Venture Capital, Lava Therapeutics, Lawson Health Research Institute, Laxai Pharma, LBT Innovations, Lead Discovery Center, Lead Pharma, Lee Moffitt Cancer Center, LegoChem Biosciences, Lehigh University, Leibniz-Institut fur Molekulare Pharmakologie, Leicester University, Leiden University, Leidos, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Lesaffre, Les Laboratoires Servier, Leukemia & Lymphoma Society, LexaGene, Lexogen, LGC, LG Life Sciences, Lhasa, Lieber Institute, LifeArc, LifeMap Sciences, Ligand Pharmaceuticals, Li Ka Shing Foundation, Lineage Cell Therapeutics, LineaRx, LipimetiX Development, Lipotype, Liverpool School of Tropical Medicine, Livongo Health, LNC, Locate Therapeutics, Lockheed Martin, Locus Biosciences, Lodo Therapeutics, LogicBio Therapeutics, Lonza, Louisiana State University, Loulou Foundation, Loxo Oncology, Ludwig-Maximilians University, Ludwig Institute for Cancer Research, LumiThera, Lunaphore, Lundbeck, Lund University, Lunenfeld-Tanenbaum Research Institute, Lung Biotechnology, Lung Cancer Research Foundation, LUNGevity Foundation, Lupin Pharmaceuticals, Lupus Foundation of America (LFA), Luye Pharma Group, Lyfebulb, Lynkogen, Lysando, Lysogene, M2Gen, MAB Discovery, Mabspace Bioscience, MabVax Therapeutics, Machavert Pharmaceuticals, Macroceutics, Macrogenics, Macrolide Pharma, Magenta Therapeutics, Maisonneuve-Rosemont Hospital (HMR), Mallinckrodt Pharmaceuticals, Mammoth Biosciences, Marina Biotech, Mark Foundation for Cancer Research, Marshall Institute for Interdisciplinary Research, Marshall University, Mars Symbioscience, Maruho, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, MassBiologics, Max-Planck, Maxcyte, Max Planck Institute of Biochemistry, Mayo Clinic, McGill University, McKesson, McLean Hospital, MD Anderson Cancer Center, Medacta, Medgenics, Medicago, Medical Research Foundation, Medical University of Graz, Medical University of Innsbruck, Medical University of South Carolina, Medical University South Carolina, Medicinal Genomics, Medicine by Design, Medicines Discovery Catapult, Medifocus, Medi Futures, MediGene, Medimabs, MedImmune, MediSix Therapeutics, Medivation, Medivir, Medline Industries, Medopad, Medtronic, Meiji Seika, Meiogenix, MeiraGTx, Melanoma Research Alliance, Melanoma Research Foundation, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, MercachemSyncom, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Merus, Metabolon, Methodist Hospital Houston, Metrion Biosciences, MGI Pharma, Michael J Fox Foundation, Microbiotica, Microchips Biotech, MicroConstants, Microlin Bio, MicroMGx, Microsoft, Midatech, Midwest Melanoma Partnership, Millennium, MilliporeSigma, Milner Therapeutics Institute and Consortium, Mimetas, MiNA Therapeutics, MiNDERA, MindImmune Therapeutics, Minerva Biotechnologies, MinervaX, Minnetronix, Miragen Therapeutics, MirImmune, Mironid, MiRXES, Mission Therapeutics, MIT, Mitacs, Mitobridge, Mitra Biotech, Mitsubishi Tanabe Pharma, Moderna Therapeutics, ModiQuest Research, Modulus Discovery, Molecular Templates, Moleculin Biotech, Molplex Pharmaceuticals, Monash University, Monsanto, Montreal Heart Institute, Montreal Neurological Institute-Hospital, Moores Cancer Center, Morphic Therapeutic, MorphoSys, Morphotek, Morris Animal Foundation, Mount Sinai Health System, Mount Sinai Medical Center, MSD Action Foundation (MSDAF), Multiple Myeloma Research Foundation, Munich Technical University, Murdoch Childrens Research Institute, Muscle Activation Technique, Muscular Dystrophy Association, Mustang Bio, Mustang Therapeutics, Mycoses Study Group Education & Research Consortium, Myeloma Health, Myelopro Diagnostics and Research, Mymetics, MyoKardia, MYOS, NABsys, Nagase America, Nanion, Nanjing King-friend Biochemical Pharmaceutical, Nanna Therapeutics, NanoCellect Biomedica, NanoMab Technology, nanoPET Pharma, NanoString Technologies, Nanotherapeutics, Nansen Neuroscience Network, NantBioScience, NantCell, Nantes University, NantKwest, Nantong Jinghua Pharmaceutical, NantWorks, NapaJen Pharma, Napa Therapeutics, Narayana Nethralaya Foundation, Nashville Biosciences, National Brain Tumor Society, National Cancer Centre Singapore, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Cardiovascular Diseases, National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Eye Institute, National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute for Health Research (NIHR), National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Innovation, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Health Research, National Institute of Mental Health, National Institute of Molecular Genetics, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Kidney Foundation, National Organization for Rare Disorders, National Psoriasis Foundation, National Research Council Canada, National Resource Center For Mutant Mice (NRCMM), National Science Foundation, National University of Singapore, Nationwide Children’s Hospital, Natrix Separations, Naval Medical Research Center, Navitor Pharmaceuticals, Navy Medical Research Centre, NBE Therapeutics, Ncardia, NCIC Clinical Trials Group, Nebula Genomics, NEC, Necker Hospital, Neogenomics, NEO New Oncology, NeoPhore, Neoteryx, Nephrogenex, Neptune Technologies & Bioressources, Nerviano Medical Sciences, Nestle, Nestle Health Science, Netherlands Cancer Institute, NetScientific, NetVation DL Medicine, NeuCyte, NeurAegis, Neuraly, NeurExo Sciences, Neurimmune Therapeutics, Neurocrine Biosciences, NeuroEM Therapeutics, Neuropore Therapies, NeuroTrauma, NeuroVigil, NeuroVive Pharmaceutical, NeuX Technologies, Nevakar, New England Biolabs, Newomics, New Paradigm Therapeutics, New York Blood Center, New York Genome Center (NYGC), New York University, New York University School of Medicine, NextCure, Nextera, Nexvet, NGM Biopharmaceuticals, Nimbus Therapeutics, Nipro Corporation, Nitrome Biosciences, Nkarta Therapeutics, NMI Natural and Medical Sciences Institute, Nodality, Noile-Immune Biotech, Nordic Nanovector, Noria Pharmaceuticals, Northern Biologics, Northern California Institute for Research and Education, North Shore-LIJ Cancer Institute, Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, Norwegian Research Council, Notal Vision, Notch Therapeutics, Nouscom, Novan Therapeutics, NovaRock Biotherapeutics, Novartis, NovImmune, Novogen, Novoheart, Novo Nordisk, Novoron Bioscience, Nuclea Biotechnologies, Nuevolution, Numab, NuMedii, Numerate, NuProbe, Nurix, Nuvilex, NXT Biomedical, NYU Langone Medical Center, Obsidian Therapeutics, Ocugen, Ogeda, Ohio State University, Omdana Therapeutics, OMRF, Omthera Pharmaceuticals, Oncodesign, OncoFusion, OncoImmunity, Oncologie, Oncology Research Information Exchange Network, OncoQuest, Oncora Medical, OnCore Biopharma, OncoRx, OncoSec Medical, OncoStatyx, Oncosynergy, Oncothyreon, Oncovita, One Drop, One Way Liver Genomics (OWL), One World Lab, Ono Pharmaceutical, Ontario Brain Institute (OBI), Opal Therapeutics, Open Commons Consortium, OpenEye Scientific Software, Open Medicine Institute, Open Monoclonal Technology, OpGen, Ophthotech, OPKO Health, Optasia Medical, OptiBiotix, Optibrium, OptiKira, Optina Diagnostics, Oragenics, Orca Pharmaceuticals, Orchard Therapeutics, Orebro University, Oregon Health Sciences University, Oregon National Primate Research Center, Oregon State University, Organic Vaccines, Organovo, Orgenesis, ORIG3N, Origenis, Origin Agritech, Orion, OrthoCyte, Orthopaedic Research and Education Foundation, Oryzon, OSE Immunotherapeutics, Oslo University Hospital, Ossianix, Osteosarcoma Collaborative, Otologic Pharmaceutics, Otsuka, Owlstone Medical, Oxford BioMedica, Oxford BioTherapeutics, Oxford Drug Design, Oxford Gene Technology, Oxford Genetics, Oxford Nanopore Technologies, Oxford Sciences Innovation, Oxford University Hospitals NHS Trust, Oxitec, Oxurion, Oxygen Healthcare, OZ Biosciences, Padlock Therapeutics, Paidion Research, Pairwise Plants, Palleon Pharmaceuticals, panCELLa, Pancreatic Cancer Action Network, Pancreatic Cancer Collective, Pandion Therapeutics, Parent Project Muscular Dystrophy, Parexel, Paris Descartes University, Parkinson's Disease Foundation, Parkinson's Institute, Parkinson's Institute and Clinical Center, Partek, Partners HealthCare, Parvus Therapeutics, Pascal Biosciences, Passage Bio, Pathios Therapeutics, PathoQuest, PatientsLikeMe, Paul G Allen Family Foundation, Paul Scherrer Institute, PAVmed, PCI Biotech, Pcovery, Peakdale Molecular, Peking University, Penn Medicine, Penn State College of Medicine, Pennsylvania State University, PeptiDream, Peptinnovate, PercayAI, Perelman School of Medicine, PeriGen, PerkinElmer, Perlara, Personal Genome Diagnostics, Personalis, PetaGene, Petco, Peter MacCallum Cancer Institute, Petra Pharma, Pfizer, Phanes Therapeutics, Pharmacological research Institute Mario Negri, Pharmasum Therapeutics, PharmAthene, PhaseBio Pharmaceuticals, Pherecydes Pharma, Philogen, Phio Pharmaceuticals, PhoreMost, PhosImmune, pH Pharma, Phylogica, Phytola, Pieris, Pierre Fabre, Pinnacle Clinical Research Center, Pioneer Hi-Bred, Pionyr Immunotherapeutics, Pistoia Alliance, Pivot Bio, Plant Response Biotech, PlasmaTech Biopharmaceuticals, Plasticell, Platelet BioGenesis, Plexxikon, Pliant Therapeutics, Pluriomics, PMV Pharma, Poietis, Polyphor, Portage Biotech, Poseida Therapeutics, Poseidon Innovation, Potenza Therapeutics, Poxel, PPD, Precigen, Precision BioSciences, Precision for Medicine, Precision Therapeutics, PredictImmune, Premier Biosoft International, Premier Inc, Presage Biosciences, Pressure BioSciences, Prevail Therapeutics, PreveCeutical Medical, Prime Medicine, Primetime Life Sciences, Princess Maxima Center for Pediatric Oncology, Princeton University, Prince William Science Accelerator, Probi, Probiodrug, ProBioGen, Procarta Biosystems, Procter & Gamble, Profectus Biosciences, Profil Institute for Clinical Research, Progknowse, Prognos, Prokaryotics, ProMab Biotechnologies, Promega, Prometheus Laboratories, Promosome, Pronutria, Propanc Health Group, ProQinase, ProQR Therapeutics, Prosenex, ProSensa, Prostate Cancer Foundation (PCF), Protagen, Protea Biosciences, Protein Sciences, Proteostasis Therapeutics, Proteros biostructures, ProtoKinetix, Provenance Biopharmaceuticals, Proximagen Group, Proximagen Neuroscience, PsychoGenics, PTC Therapeutics, Pulmatrix, Purdue Pharma, Purdue Research Foundation, Purdue University, Pure MHC, PureTech Health, Q-State Biosciences, Qiagen, Qpex Biopharma, QPS, Q Therapeutics, Quadrant Biosciences, Qualyst Transporter Solutions, Quanterix, Quartet Medicine, Qu Biologics, Quebec Consortium for Drug Discovery, Quebec Urological Association Foundation, Queen Mary University of London, Queensland Institute of Medical Research (QIMR), Queensland University of Technology, Queens University, Queens University Belfast, Quest PharmaTech, Quimica Europea, Qurient, R-Biopharm, Radboud University Nijmegen Medical Centre, Rady Children's Institute for Genomic Medicine, Ragon Institute, Rallybio, Rambam Medical Center, Ramot at Tel Aviv University, Randox Laboratories, Rare Genomics Institute, Rebiotix, Recce Pharmaceuticals, Recida Therapeutics, Recombinant Technologies, Recombinetics, Recursion Pharmaceuticals, Redx Pharma, Regenacy Pharmaceuticals, Regen BioPharma, Regeneron Genetics Center, Regeneron Pharmaceuticals, Regenxbio, ReGenX Biosciences, REGiMMUNE, Regulus Therapeutics, Renew Biopharma, Renmin Hospital of Wuhan University, Renovacare, Renova Therapeutics, Renown Institute for Health Innovation, Repare Therapeutics, Repertoire Genesis, Replicel Life Sciences, Repositive, ReproCell, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Research Corporation Technologies, Research Council of Norway, Research Institute of McGill University Health Centre (RI MUHC), Research Institute of the Hospital Universitari Vall d'Hebron, Reset Therapeutics, Resilience Therapeutics, Resonant Therapeutics, Retrogenix, Retrophin, RetroSense Therapeutics, Rett Syndrome Research Trust, rEVO Biologics, Revolution Medicines, Rexgenero, Rheos Medicines, Rheumatology Research Foundation, Rhythm Pharmaceuticals, Ribometrix, Rice University, Rigel Pharmaceuticals, RIKEN Yokohama Institute Omics Science Center, Robert H. Lurie Comprehensive Cancer Center, Roche, Rockefeller University, Rockland Immunochemicals, Rodin Therapeutics, Roivant Sciences, Rosa, Rosetta Genomics, Roswell Park Cancer Institute, Royal Children’s Hospital, Royal College of Surgeons (Ireland), Royal Free Hospital, Royal Philips Electronics, Rugen Therapeutics, Rutgers University, RXi Pharmaceuticals, Saban Research Institute of Children's Hospital Los Angeles, SAB Biotherapeutics, SAB Therapeutics, Saint Louis University, Salix Pharmaceuticals, Salk Institute, SAMDI Tech, Sana Biotechnology, San Diego Biomedical Research Institute, Sanford Burnham Institute, Sangamo BioSciences, Saniona, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Santaris Pharma, Santen Pharmaceutical, Santhera Pharmaceuticals, Sapphire Biotech, Sarepta Therapeutics, Saromics, Sartorius Stedim Biotech, Scaled Biolabs, Schepens Eye Research Institute, Scholar Rock, Schrodinger,, Sciex, Scil Proteins, ScinoPharm Taiwan, Scleroderma Research Foundation, SCM Pharma, Scottish Enterprise, Screen Therapeutics, Scripps Research Institute, Sea Lane Biotechnologies, Sean N Parker Center for Allergy Research, Seattle Children's Hospital, Seattle Childrens Research Institute, Seattle Genetics, Secant Medical, Secarna Pharmaceuticals, Second Genome, Second Sight Medical, Seegene, SEEK, Selecta Biosciences, Selecxine, Selexis, SELLAS Life Sciences Group, Selvita, Sema4, Semma Therapeutics, Semmelweis University, Sengenics, SEngine Precision Medicine, Senhwa Biosciences, SensiQ Technologies, Sensyne Health, Sentinel Oncology, Seoul National University, Sequenom, Seraxis, Seres Therapeutics, Serono, Serum Institute of India, SETUBIO, Sevion Therapeutics, Shaanxi Research Institution of Chinese Traditional Medicines, Shanghai Cancer Institute, Shanghai ChemPartner, Shanghai Institute of Organic Chemistry, Shanghai Institutes of Preventative Medicine, Shanghai Miracogen, Shanghai Model Organisms Center, Shanghai RAAS Blood Products, ShanghaiTech University, ShangPharma, Shanxi Yabao Pharmaceutical Distribution, Sharp Edge Labs, Shattuck Labs, Shionogi, Shire Laboratories, Shire Pharmaceuticals, Shuwen Biotech, Siamab Therapeutics, Sidney Kimmel Cancer Center, Sigilon Therapeutics, Sigma-Aldrich, SilcsBio, Silence Therapeutics, Simon Fraser University, Simulations Plus, Singapore Eye Research Institute (SERI), Singapore General Hospital, Singulex, Sinobioway, Sirenas, Sirion Biotech, Sirona Biochem, Siteman Cancer Center, SK Biopharmaceuticals, Skolkovo Foundation, Skyhawk Therapeutics, Skysong Innovations, Smartox Biotechnology, SmartZyme BioPharma, Sohn Conference Foundation, Solarvest BioEnergy, Soleno Therapeutics, Solentim, Solid Biosciences, SomaGenics, SomaLogic, Soonchunhyang University Hospital Bucheon, Sorrento Therapeutics, Sosei, Sosei Heptares, SOTIO, Southern Research Institute, Spanish National Cancer Research Centre, Spark Therapeutics, SpeeDx, Spero Therapeutics, Sphingotec, SpiroChem, Sprint Biosciences, SQZ Biotech, SRI International, St. Baldrick's Foundation, St. Jude Children's Research Hospital, Stallargenes, Stanford Cancer Institute, Stanford University, Stanford University School of Medicine, Starpharma, Stealth Therapeutics, Stem Cell Medicine, Stemcell Technologies, StemoniX, StemSynergy, Stevenage Bioscience Catalyst, St Jude Crosson Cancer Institute, St Michael's Hospital, Stockholm University, Stony Brook University, Strategia, STRATIFYER Molecular Pathology, StrideBio, Structural Genomics Consortium, Structured Immunity, St Vincent’s Institute of Medical Research, Sud Investments, Summit Therapeutics, Sunnybrook Research Institute, Sunovion Pharmaceuticals, Sun Pharma Advanced Research Company, SUNY Upstate Medical University, Surface Oncology, Susan G. Komen for the Cure, Sutro Biopharma, Suzhou NeuPharma, SV Life Science, Sway Medical, Swedish Orphan Biovitrum, Syapse, Sygnature Discovery, Symphogen, Synaffix, Synbiotic Health, Syncona Partners, Syndesi Therapeutics, Synergy Partners R&D Solutions, Syngenta, Syngulon, Synlogic, Synpromics, Synthego, Synthetic Biologics, Synthetic Genomics, Syros Pharmaceuticals, Systimmune, Taconic Biosciences, Taiho, TaiRx, Taisho Pharmaceutical, Takeda America Holdings, Takeda Pharmaceutical, Takeda Ventures, Takis, Talem Therapeutics, TamRx, Tanabe Research Laboratories, Tango Therapeutics, TAP Biosystems, TARA Biosystems, Targacept, Targazyme, Target ALS Foundation, TARGET PharmaSolutions, Targovax, TARIS Biomedical, Taros Chemicals, Tau Consortium, TB Alliance, TBD Biodiscovery, TC BioPharm, Team Sanfilippo, Technical University of Denmark (DTU), Technion Research and Development Foundation, Technology Foundation STW, Technology Strategy Board (UK), Technology Transfer Accelerator, Technology University Dresden, TechnoVax, Teijin, Tel Aviv Sourasky Medical Center, Tel Aviv University, Telix Pharmaceuticals, Temple University, Tempus, Tencent Holdings, TeneoBio, Tesaro, TeselaGen, TES Pharma, Tessa Therapeutics, Tetra Discovery Partners, Tetragenetics, Teva Pharmaceutical Industries, Texas A&M University, Texas Children’s Hospital, Texas Christian University, TG Therapeutics, The American Senior Housing Association, The Global Stem Cell and Regenerative Medicine Acceleration Center (GSRAC), The Haematological Malignancy Research Network, The Human Protein Atlas, The International AIDS Vaccine Initiative, The Medicines Company, Themis Bioscience, The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, Theradiag, Theravectys, The Regents of the University of California, Theresia G & Stuart F Kline Family Foundation, Thermo Fisher Scientific, The Silverstein Foundation for Parkinson's, The University of Chicago Medicine, Thiel Foundation, Thomas Jefferson University, Thought Leadership & Innovation Foundation, Thrive Bioscience, ThromboGenics, Tianjin CanSino Biotechnology, Tianjin University, Tillotts Pharma, Tissue Regeneration Systems, Titian Software, Tiziana Life Sciences, Tizona Therapeutics, T Med, Tmunity Therapeutics, TNK Therapeutics, TNO Pharma, TomegaVax, Toolgen, TopAlliance Biosciences, Torch Biosciences, Toronto Innovation Acceleration Partners, Torrey Pines Institute for Molecular Studies, Torrey Pines Investment, Tor Vergata University Hospital, Toulouse University Hospital, Tow Foundation, Toyota Motor, TPG Biotech, TRACON Pharmaceuticals, Trakcel, TransBio, TransChem, Transcriptic, Transgene, Transgenomic, Translate Bio, Translational Genomics Research Institute, Translatum Medicus, Transporin, Transposagen Biopharmaceuticals, TransTech Pharma, Trefoil Therapeutics, Trellis Bioscience, Trenzyme, Treventis, Tri-Institutional Therapeutics Discovery Institute, Trianni, Trieza Therapeutics, Triphase Accelerator, TrojanTec, Tsinghua University, Tuberous Sclerosis Alliance (TS Alliance), Tubulis, Tu Dresden, Tufts University, TuHURA Biopharma, TumorGenesis, Turku PET Center, Turnstone Biologics, Twist Bioscience, twoXAR, TxCell, Tyber Medical, Ubiquigent, UbiVac, UCB, UH Harrington Discovery Institute, UK Cystic Fibrosis Gene Therapy Consortium, UK Government, Ultragenyx Pharmaceuticals, UMN Pharma, UNeMed, UNICANCER, UniQuest, UniQure, Univeristy of Durham, Universal Cells, Universite Claude Bernard Lyon, Universite Laval, University Ann & Robert H. Lurie Children’s Hospital, University City Science Center, University College Cork, University College London, University Gottingen, University Health Network, University Hospitals Rainbow Babies & Children's Hospital, University Medical Center Groningen, University Medical Center Utrecht, University of Alabama, University of Alabama at Birmingham, University of Alberta, University of Amsterdam, University of Arizona, University of Arkansas, University of Barcelona, University of Basel, University of Bonn, University of Bristol, University of British Columbia, University of Buffalo, University of California, University of California, Davis, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of California Santa Cruz, University of Cambridge, University of Chicago, University of Cincinnati, University of Colorado, University of Colorado Denver, University of Connecticut, University of Debrecen, University of Dundee, University of Eastern Finland, University of Edinburgh, University of Exeter, University of Florida, University of Florida Research Foundation, University of Geneva, University of Greifswald, University of Heidelberg, University of Hong Kong, University Of Huddersfield, University of Illinois, University of Illinois Urbana-Champaign, University of Iowa, University of Jaen, University Of Jyvaskyla, University of Kansas, University of Kentucky, University of Kiel, University of Leeds, University of Leipzig, University of Manchester, University of Manitoba, University of Maryland, University of Maryland Baltimore, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Miami, University of Michigan, University of Michigan Medical School, University of Minnesota, University of Montreal, University of Nagasaki, University of Nebraska, University of New Hampshire, University of New Mexico, University of New South Wales, University of North Carolina, University of Northern Colorado, University of North Texas Health Science Center, University of Notre of Dame, University of Nottingham, University of Oklahoma, University of Oslo, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Quebec, University of Queensland, University of Rennes, University of Rochester, University of Rostock, University of Sheffield, University of Sherbrooke, University of South Alabama (USA) Mitchell Cancer Institute, University of Southampton, University of South Australia, University of South Carolina, University of South Carolina Research Foundation, University of South Florida, University of Technology Sydney, University of Tennessee, University of Texas, University of Texas Health SCience Center at San Antonio, University of Texas Southwestern Medical Center, University of the Witwatersrand, University of Tokyo, University of Torino, University of Toronto, University of Tubingen, University of Turin, University of Utah, University of Verona, University of Virginia, University of Warsaw, University of Washington, University of Wisconsin, University of Wisconsin-Madison, University of Zurich, UPMC, Uppsala University, UroGen Pharma, US Army, US Army Medical Research Institute of Infectious Diseases, US Department of Commerce, US Department of Veteran Affairs, Utah Genome Project, UT Southwestern Medical Center, UW Medicine, Vaccinex, Vaccitech, Valera Pharmaceutical, Validogen, Valitacell, Vall d’Hebron Research Institute, Valo Therapeutics, VA Medical Center (VAMC), Vanderbilt University, Varian Medical Systems, Variant Pharmaceuticals, Vascugen, Vasomune Therapeutics, Vaxeal, Vaximm, VBI Vaccines, Vect-Horus, Vedanta Biosciences, Velabs Therapeutics, VenatoRx, venBio, Venomtech, Ventana Medical Systems, Veracyte, Verastem, Verge Genomics, Verily, Veritas Genetics, Vernalis, Versant Ventures, Verseau Therapeutics, Versiti Blood Research Institute, Vertex Pharmaceuticals, V Foundation for Cancer Research, ViaCyte, Viamet Pharmaceuticals, VIB, Vibalogics, Vical, Victoria University, Viela Bio, View Medical, Vifor Pharma, Vigene Biosciences, ViiV Healthcare, Viking Therapeutics, Vinnova, Viome, ViraCyte, Vir Biotechnology, Virginia Catalyst, Virginia Commonwealth University, Viscient Biosciences, Visionary Pharmaceuticals, VistaGen Therapeutics, Visterra, Vitrisa Therapeutics, Vitro, Vium, Vividion Therapeutics, Vivoryon Therapeutics, VLP Therapeutics, Voyager Therapeutics, Voyant Biotherapeutics, Vtesse, VU Medical Center, VU University Amsterdam, Vycellix, WaferGen Biosystems, Wageningen University, Wake Forest University, Wallace H. Coulter Foundation, Walter Reed Army Institute of Research, Warp Drive Bio, Warren Family Research Center for Drug Discovery and Development, Washington Research Foundation, Washington State University, Washington University in St Louis, WAVE Life Sciences, Wayne State University, WCCT Global, Wearifi, Weill Cornell Medical College, Weizmann Institute, Wellcome Trust, Wellcome Trust Sanger Institute, Western Digital, Weston Brain Institute, Whitehead Institute, WindMIL Therapeutics, WinterLight Labs, Wisconsin Alumni Research Foundation, Wistar Institute, W L Gore, Woodland Biosciences, WUGEN, Wuxi Apptec Laboratory Services, WuXi Biologics, WuXi NextCODE Genomics, Wyss Institute, X-chem, X4 Pharmaceuticals, Xcell Biosciences, Xencor, Xenon Pharmaceuticals, Xoma, XRGenomics, XtalPi, Xyphos, Y-Biologics, Y-Trap, Yabao Pharmaceutical, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yield10 Bioscience, Yifan Pharmaceutical, Yissum Research Development, Ymir Genomics, YOFOTO (China) Health Industry, Yuhan Corporation, YUMAB, ZAI Laboratory, Zealand Pharma, ZebiAI Therapeutics, Zebra Biologics, ZeClinics, Zedira, Zellkraftwerk, Zelluna Immunotherapy, Zenoaq, Zenyaku Kogyo, Zhejiang Hisun Pharmaceutical, Ziopharm Oncology, ZoBio, Zoetis, Zymergen, Zymeworks, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.